5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.92▼ | 1.91▼ | 1.96▼ | 1.94▼ | 1.93▼ |
MA10 | 1.91▼ | 1.97▼ | 1.97▼ | 2.00▼ | 1.97▼ |
MA20 | 1.91▼ | 1.96▼ | 1.95▼ | 1.97▼ | 1.91▲ |
MA50 | 1.96▼ | 1.96▼ | 1.99▼ | 2.00▼ | 1.66▲ |
MA100 | 1.95▼ | 2.01▼ | 2.00▼ | 1.90▲ | 2.22▼ |
MA200 | 1.97▼ | 1.99▼ | 2.08▼ | 1.63▲ | 4.18▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | -0.009▼ | 0.000▼ | -0.009▼ | -0.008▼ |
RSI | 42.588▼ | 40.302▼ | 41.303▼ | 45.863▼ | 51.893▲ |
STOCH | 56.111 | 19.336▼ | 44.752 | 20.416 | 32.152 |
WILL %R | -66.667 | -93.103▼ | -82.609▼ | -86.207▼ | -74.016 |
CCI | 0.000 | -106.359▼ | -66.870 | -90.472 | -21.536 |
Wednesday, May 15, 2024 01:54 PM
ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never ...
|
Wednesday, May 15, 2024 06:47 AM
CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...
|
Wednesday, May 15, 2024 04:00 AM
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/05/24 | 2.01 | 2.02 | 1.90 | 1.91 | 521,694 |
15/05/24 | 2.00 | 2.10 | 1.85 | 2.05 | 1,659,103 |
14/05/24 | 1.93 | 2.00 | 1.90 | 1.91 | 398,703 |
13/05/24 | 1.975 | 2.02 | 1.925 | 1.93 | 426,263 |
10/05/24 | 2.09 | 2.10 | 1.89 | 1.89 | 666,666 |
09/05/24 | 2.00 | 2.065 | 1.975 | 2.05 | 333,324 |
08/05/24 | 2.05 | 2.0892 | 2.00 | 2.01 | 345,684 |
07/05/24 | 2.10 | 2.1402 | 2.01 | 2.05 | 731,767 |
06/05/24 | 2.10 | 2.16 | 2.07 | 2.12 | 478,368 |
03/05/24 | 2.16 | 2.285 | 2.02 | 2.05 | 1,176,870 |
|
|
||||
|
|
||||
|
|